Seeking Alpha


Send Message
View as an RSS Feed
Latest  |  Highest rated
  • The FDA has approved J&J's (JNJ) Invokana drug for treating type 2 diabetes in a new way by causing the body to excrete blood sugar via the urine rather than affecting the supply or use of insulin. The agency said J&J must carry out five post-marketing studies to determine whether the drug increases the risks of strokes, heart attacks and other side effects. Invokana is forecast to generate sales of $667M by 2016. [View news story]
    A novel treatment modality for a chronic illness that is becoming a pandemic.... what is not to like about the company's prospects going forward. (Of course, safety and efficacy testing after the drug is FDA approved for prescription use will be ongoing and may turn up some adverse events. But being the first to market has such a huge economic advantage that profits will likely create a cash cow large enough to offset any future liabilities.)
    Apr 1, 2013. 04:59 AM | Likes Like |Link to Comment
1 Comment